CN1539474A - 一种治疗冠心病心绞痛的药物及其制备方法 - Google Patents
一种治疗冠心病心绞痛的药物及其制备方法 Download PDFInfo
- Publication number
- CN1539474A CN1539474A CNA2003101054551A CN200310105455A CN1539474A CN 1539474 A CN1539474 A CN 1539474A CN A2003101054551 A CNA2003101054551 A CN A2003101054551A CN 200310105455 A CN200310105455 A CN 200310105455A CN 1539474 A CN1539474 A CN 1539474A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- angina pectoris
- heart disease
- coronary heart
- treating coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 46
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 17
- 229940079593 drug Drugs 0.000 title description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 43
- 241000218176 Corydalis Species 0.000 claims abstract description 39
- 238000001035 drying Methods 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 20
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 4
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 35
- 241000208340 Araliaceae Species 0.000 claims description 30
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 30
- 235000008434 ginseng Nutrition 0.000 claims description 30
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims description 23
- 241000736148 Styrax Species 0.000 claims description 23
- 239000004870 Styrax Substances 0.000 claims description 23
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008361 herbal raw material Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 2
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 244000303379 Styrax officinalis Species 0.000 abstract 1
- 235000001361 Styrax officinalis Nutrition 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 235000019382 gum benzoic Nutrition 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 28
- 230000036407 pain Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 18
- 238000002481 ethanol extraction Methods 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 230000010354 integration Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010008479 Chest Pain Diseases 0.000 description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 7
- 239000000006 Nitroglycerin Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 229960003711 glyceryl trinitrate Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 208000035286 Spontaneous Remission Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- KWEUUBDPVVHQAL-MSQVLRTGSA-K trisodium;[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O KWEUUBDPVVHQAL-MSQVLRTGSA-K 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310105455 CN1227023C (zh) | 2003-10-28 | 2003-10-28 | 一种治疗冠心病心绞痛的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310105455 CN1227023C (zh) | 2003-10-28 | 2003-10-28 | 一种治疗冠心病心绞痛的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539474A true CN1539474A (zh) | 2004-10-27 |
CN1227023C CN1227023C (zh) | 2005-11-16 |
Family
ID=34333741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310105455 Expired - Lifetime CN1227023C (zh) | 2003-10-28 | 2003-10-28 | 一种治疗冠心病心绞痛的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1227023C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084992B (zh) * | 2006-06-08 | 2012-03-07 | 天津天士力制药股份有限公司 | 一种含有红花和人参的药物组合物、制备方法和制剂 |
CN102600420A (zh) * | 2012-04-01 | 2012-07-25 | 李承平 | 一组血瘀气滞药物组合 |
CN102961451A (zh) * | 2012-12-14 | 2013-03-13 | 山东宏济堂制药集团有限公司 | 一种用于冠心病心绞痛的中药组合物 |
CN105726901A (zh) * | 2016-05-17 | 2016-07-06 | 李晓维 | 一种缓解冠心病心绞痛的中药组合 |
-
2003
- 2003-10-28 CN CN 200310105455 patent/CN1227023C/zh not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084992B (zh) * | 2006-06-08 | 2012-03-07 | 天津天士力制药股份有限公司 | 一种含有红花和人参的药物组合物、制备方法和制剂 |
CN102600420A (zh) * | 2012-04-01 | 2012-07-25 | 李承平 | 一组血瘀气滞药物组合 |
CN102961451A (zh) * | 2012-12-14 | 2013-03-13 | 山东宏济堂制药集团有限公司 | 一种用于冠心病心绞痛的中药组合物 |
CN105726901A (zh) * | 2016-05-17 | 2016-07-06 | 李晓维 | 一种缓解冠心病心绞痛的中药组合 |
Also Published As
Publication number | Publication date |
---|---|
CN1227023C (zh) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1290558C (zh) | 一种治疗慢性疲劳综合征的复方中药制剂 | |
CN101032560A (zh) | 一种治疗睡眠障碍的中药组合物及制备方法 | |
CN1915399A (zh) | 治疗高血压、高血脂、肥胖症及更年期综合症的制剂及其制备方法 | |
CN101032580A (zh) | 一种治疗风湿性疾病的药物 | |
CN101822789B (zh) | 一种治疗原发性高血压的降压药 | |
CN1297291C (zh) | 一种戒除毒瘾的药物及其制备方法 | |
CN1709404A (zh) | 一种防治中风疾病的中成药及其生产方法、用途 | |
CN1726929A (zh) | 一种治疗糖尿病的药物组合物 | |
CN1927331A (zh) | 一种治疗慢性心力衰竭的中药制剂 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1232267C (zh) | 用于治疗脑血管疾病的组合物及其制备方法和应用 | |
CN1706435A (zh) | 一种治疗经前期紧张综合征的中药组合物及其制备方法 | |
CN1227023C (zh) | 一种治疗冠心病心绞痛的药物及其制备方法 | |
CN1297290C (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1232279C (zh) | 一种降血脂的中药 | |
CN102048939B (zh) | 一种治疗窦性心动过缓药物 | |
CN1478533A (zh) | 一种治疗颈椎病的中药及其制备方法 | |
CN1287827C (zh) | 一种补血中药制剂及其生产方法 | |
CN1276775C (zh) | 一种治疗眼底出血症的中药及其制备方法 | |
CN1256143C (zh) | 抗病毒的中药复方制剂 | |
CN1451422A (zh) | 一种治疗眼底出血症的中药及其制备方法 | |
CN1232283C (zh) | 治疗冠心病心绞痛的中药 | |
CN1899581A (zh) | 用于气滞寒凝胃痛的药物组合物及其制备方法和用途 | |
CN1282470C (zh) | 一种抗抑郁中药及其制备方法 | |
CN1416879A (zh) | 一种降血脂中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANDONG HONGJITANG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: HONGJITANG PHARMACY CO., LTD., JINAN |
|
CP01 | Change in the name or title of a patent holder |
Address after: 250100 No. 360, Hualong Road, Licheng District, Shandong, Ji'nan Patentee after: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. Address before: 250100 No. 360, Hualong Road, Licheng District, Shandong, Ji'nan Patentee before: Jinan Hongjitang Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Licheng District 250103 Shandong city of Ji'nan province by ten Road No. 30766 Patentee after: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. Address before: 250100 No. 360, Hualong Road, Licheng District, Shandong, Ji'nan Patentee before: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 250103 No. 360, Hualong Road, Ji'nan, Shandong Patentee after: SHANDONG HONGJITANG PHARMACEUTICAL GROUP Co.,Ltd. Address before: 250103 No. 360, Hualong Road, Ji'nan, Shandong Patentee before: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051116 |